Sort   by:  
 Page size 
UnknownPhase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial.
Not available
S-EPMC3635682 | biostudies-literature
GenomicsEGAD00000000055
COLO-829 is a publicly available immortal cancer cell line and COLO-829BL is a lymphoblastoid cell line derived from the same patient
EGAD00000000055 | EGA
GenomicsA Comprehensive Catalogue of Somatic Mutations from a Human Cancer Genome
We have carried out complete sequencing of the genome of the human male maligant melanoma cell line COLO-829 using the Illumina Genome Analyzer II. We generated a sequencing library with a median insert size of ~200 bp following random fragmentation and gel fractionation of the genomic DNA. We seque...
EGAS00000000052 | EGA
GenomicsNational Cancer Institute (NCI) TARGET: Therapeutically Applicable Research to Generate Effective Treatments

The Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative seeks to accelerate research in novel marker and drug development, along with understanding the molecular basis of pediatric malignancy, through identification of genomic changes associated with the follo...

phs000218.v5.p1 | EGA
Genomicsena-DATASET-RTL-13-12-2013-10:28:27:441-48 - samples
SCLC - Whole genome sequencing data Publication Peifer et al., 2012, Nature Genetics
EGAD00001000703 | EGA
Genomicsena-DATASET-RTL-02-07-2015-13:42:15:919-50 - samples
SCLC - RNA sequencing data Publication Peifer et al., 2012, Nature Genetics
EGAD00001001431 | EGA
GenomicsSCLC_6.0 - samples
SNP 6.0 arrays of small cell lung cancer
EGAD00010000526 | EGA
GenomicsIntegrative analysis of small cell lung cancer
Small-cell lung cancer (SCLC) is an aggressive lung tumor subtype. We conducted integrated analysis of genome sequencing, transcriptome, and copy number analysis and found an extremely high mutation rate of 7.4±1 protein-changing mutations per million basepairs. Evidence for inactivation of TP53 and...
EGAS00001000299 | EGA
UnknownGenetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing.
Not available
S-EPMC6463297 | biostudies-literature
UnknownAzithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC7884931 | biostudies-literature
Sort   by:  
 Page size